Last call for registrations to Pre-Filled Syringes East Coast conference

SMi Group8 - 9 April 2019, Boston, USA.
SMi's global portfolio of events on Pre-Filled Syringes secured an audience of over 300 senior drug delivery and medical device experts over the last year. Next week will be held the 6th annual Pre-Filled Syringes East Coast conference and exhibition where industry leaders from pharmaceutical, biotech and device manufacturing, meet to get updates on medical devices advances, parenteral drug delivery, share experiences and network. Organisers encourage everyone involved in the industry not to miss out on this premier platform as only limited number of delegate places remain. For those interested in attending, contact Kieran Ronaldson on +44 (0) 20 7827 6744 or book on the Pre-Filled Syringes East Coast conference website.

Event in brief: Over 25 presentations from a mix of leading industry players and big pharma such as - Shire, Merck, FDA, Janssen, Steri-Tek, Biogen, Sanofi, Eli Lilly, Zeon and many others.

Organisations who have recently secured some of the last few remaining places includeAmerican Regent, Credence MedSystems, Dechra, Imbrium Therapeutics, Nipro Pharma Packaging, Pfizer,Purdue Pharma, Plastic Ingenuity, Sumitomo Rubber North America, Uhlmann, W.L Gore. List of attendees available on the event website.

Over 15 exhibition stands will help navigate through supplier offers: 3P Innovation, Aptar Pharma, CSS (CONNECTICUT SPRING & STAMPING),HarroHöfliger, LONSTROFF, MITSUBISHI GAS CHEMICAL, NN Life Sciences, Owen Mumford, PHC Corporation of North America, Polyplastics, RheoSense, SCHOTT, Steri-Tek, SUMITOMO RUBBER INDUSTRIES, West Pharmaceutical Services and ZEON

To register for one of the last remaining delegate places, either call Kieran Ronaldson on +44 (0) 20 7827 6744 or book online at www.pfsamericas.com

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Novartis announces MET inhibitor capmatinib (INC28…

Novartis announced that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA). Capmatinib is ...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Can bilingualism protect the brain even with early…

A study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer's disease is the most common form of d...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...

Botanical drug is shown to help patients with head…

In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are locat...